Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind trial of evobrutinib in rheumatoid arthritis with inadequate response to methotrexate
2017-000384-32Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of evobrutinib in rheumatoid arthritis (RA) (4 arms), sponsored by Merck KGaA. Primary endpoint: ACR20-CRP response at Week 12. Started Jul 2017; status: completed.
02
Drugs
evobrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2017-000384-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000384-32.